Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868866 | 0.85 | SIRT2 (0.32) | CCR2POLBKMT2ATDP1ALDH1A1 | |
| SCHEMBL4875679 | 0.84 | GPR119 (0.43) | — | |
| SCHEMBL4876147 | 0.80 | NAMPT (0.34) | — | |
| SCHEMBL4863663 | 0.77 | PTGS2 (0.34) | CCR2SIRT2PTGS2PRMT5WDR77 | |
| SCHEMBL14194496 | 0.77 | PTGS2 (0.34) | CCR2SIRT2PTGS2PRMT5WDR77 | |
| SCHEMBL4875549 | 0.77 | RAB9A (0.41) | KMT2AALDH1A1RAB9ATSHRCYP2C19 | |
| SCHEMBL4870394 | 0.76 | KMT2A (0.31) | POLBKMT2ATDP1ALDH1A1TSHR | |
| SCHEMBL4874186 | 0.76 | RAB9A (0.40) | KMT2ARAB9A | |
| SCHEMBL4872375 | 0.75 | POLB (0.32) | POLBKMT2ATDP1ALDH1A1RAB9A | |
| SCHEMBL4866656 | 0.75 | NPC1 (0.40) | KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289965-B1 | SUBSTITUTED 1-AMINOALKYL-LACTAMS AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-10-26 | — | — | EP | disclosed |
| US-6667301-B2 | Therapy for muscular disorders, urogenital disorders, gastrointestinal disorders, respiratory system disorders | SYNTEX (U.S.A.) LLC | 2003-12-23 | — | — | US | disclosed |
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | SYNTEX (U.S.A.) LLC | 2002-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020004501-A1 | Heterocyclylalkylamines as muscarinic receptor antagonists | CHRM5, CHRM2, CHRM1 | CCR2 180/4885POLB 4520/4885KMT2A 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.